Recently, antibodies targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have been increasingly developed in tumor immunotherapy.[4] Anti-PD-1 therapies with monoclonal antibodies have been approved for the treatment of recurrent or metastatic NPC.[5–7] However, reports on immunotherapy as neoadjuvant therapy for LA-NPC are few. This evidence concerns the gene PDCD1 and nasopharyngeal carcinoma.